Cathers Brian Edwin Insider Trades

Insider Trading History

Track insider trading activity for Cathers Brian Edwin. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
Global Blood Therapeutics
Global Blood Therapeutics GBT
Chief Scientific Officer
Holding Value $1.21M 17,733 shares
Last Trade
Mar 01, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$789k 17,733 shares
$44.48
$68.49
Global Blood Therapeutics
Global Blood Therapeutics GBT
Chief Scientific Officer
Holding Value $1.03M 15,000 shares
Last Trade
Mar 01, 2021 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$167k 3,750 shares
$44.48
$68.49
Global Blood Therapeutics
Global Blood Therapeutics GBT
Chief Scientific Officer
Holding Value $911k 13,302 shares
Last Trade
Mar 01, 2021 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$167k 3,750 shares
$44.48
$68.49
Global Blood Therapeutics
Global Blood Therapeutics GBT
Chief Scientific Officer
Holding Value $822k 12,005 shares
Last Trade
Mar 01, 2021 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$57.7k 1,297 shares
$44.48
$68.49
Global Blood Therapeutics
Global Blood Therapeutics GBT
Chief Scientific Officer
Holding Value $2.13M 31,082 shares
Last Trade
Mar 01, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$1.38M 31,082 shares
$44.48
$68.49
Global Blood Therapeutics
Global Blood Therapeutics GBT
Chief Scientific Officer
Holding Value $735k 10,730 shares
Last Trade
Feb 01, 2021 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$149k 3,020 shares
$49.49
$68.49
Global Blood Therapeutics
Global Blood Therapeutics GBT
Chief Scientific Officer
Holding Value $528k 7,710 shares
Last Trade
Feb 01, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$13.2k 267 shares
$49.49
$68.49
Global Blood Therapeutics
Global Blood Therapeutics GBT
Chief Scientific Officer
Holding Value $654k 9,552 shares
Last Trade
Feb 01, 2021 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$58.3k 1,178 shares
$49.49
$68.49
Global Blood Therapeutics
Global Blood Therapeutics GBT
Chief Scientific Officer
Holding Value $1.24M 18,120 shares
Last Trade
Feb 01, 2021 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$149k 3,020 shares
$49.49
$68.49
Global Blood Therapeutics
Global Blood Therapeutics GBT
Chief Scientific Officer
Holding Value $510k 7,443 shares
Last Trade
Sep 01, 2020 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$93.8k 1,551 shares
$60.45
$68.49
Global Blood Therapeutics
Global Blood Therapeutics GBT
Chief Scientific Officer
Holding Value $359k 5,244 shares
Last Trade
Aug 20, 2020 Sale (Open Market)Shares sold on the open market or in a private sale.
$140k 2,200 shares
$63.77
$68.49
Global Blood Therapeutics
Global Blood Therapeutics GBT
Chief Scientific Officer
Holding Value $510k 7,444 shares
Last Trade
Aug 01, 2020 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$70.5k 1,045 shares
$67.48
$68.49
Global Blood Therapeutics
Global Blood Therapeutics GBT
Chief Scientific Officer
Holding Value $581k 8,489 shares
Last Trade
Aug 01, 2020 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$204k 3,020 shares
$67.48
$68.49
Global Blood Therapeutics
Global Blood Therapeutics GBT
Chief Scientific Officer
Holding Value $1.45M 21,140 shares
Last Trade
Aug 01, 2020 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$204k 3,020 shares
$67.48
$68.49
Global Blood Therapeutics
Global Blood Therapeutics GBT
Chief Scientific Officer
Holding Value $375k 5,469 shares
Last Trade
Jul 31, 2020 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$19.6k 290 shares
$67.48
$68.49
Global Blood Therapeutics
Global Blood Therapeutics GBT
Chief Scientific Officer
Holding Value $2.9M 42,400 shares
Last Trade
Jun 01, 2020 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$2.91M 42,400 shares
$68.67
$68.49
Global Blood Therapeutics
Global Blood Therapeutics GBT
Chief Scientific Officer
Holding Value $355k 5,179 shares
Last Trade
Mar 01, 2020 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$166k 2,594 shares
$63.96
$68.49
Global Blood Therapeutics
Global Blood Therapeutics GBT
Chief Scientific Officer
Holding Value $1.54M 22,500 shares
Last Trade
Mar 01, 2020 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$480k 7,500 shares
$63.96
$68.49
Global Blood Therapeutics
Global Blood Therapeutics GBT
Chief Scientific Officer
Holding Value $532k 7,773 shares
Last Trade
Mar 01, 2020 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$480k 7,500 shares
$63.96
$68.49
Global Blood Therapeutics
Global Blood Therapeutics GBT
Chief Scientific Officer
Holding Value $1.65M 24,160 shares
Last Trade
Feb 03, 2020 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$1.59M 24,160 shares
$65.82
$68.49

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up